clinical isolates of Haemophilus influenzae were collected from laboratories in France, Germany, Italy and Spain (210 isolates/country). b-Lactamase production among the isolates varied considerably by country, ranging from 8.1% in Germany to 34.8% in France. H. influenzae from patients 4 years old showed the highest prevalence of b-lactamase production (23.2%), compared with isolates from patients aged 5-17 years (17.8%) and !18 years (16.5%). All isolates were susceptible to amoxicillin-clavulanate, ciprofloxacin and levofloxacin; 99.6% and 98.9% of isolates were susceptible to azithromycin and cefuroxime, respectively. Among the macrolides tested, azithromycin (MIC 90 , 2 mg/L) was eight-fold more potent than clarithromycin (MIC 90 , 16 mg/L) and roxithromycin (MIC 90 , 16 mg/L). Despite variations in b-lactamase production between different countries, >99% of all isolates were susceptible to amoxicillin-clavulanate, ciprofloxacin, levofloxacin, and azithromycin.
Haemophilus influenzae is a common causative agent of otitis media in children and acute exacerbations of chronic bronchitis in the elderly, and is also isolated from patients with sinusitis and other community-acquired respiratory infections [1, 2] . b-Lactamase-mediated resistance in H. influenzae, encoded by TEM-1 and ROB-1, has been shown to account for most resistance to ampicillin, amoxicillin, and some oral cephalosporins [3] [4] [5] . As a result, aminopenicillins, in the absence of a blactamase inhibitor, are not used as first-line therapies for community-acquired respiratory tract infections in some countries. The prevalence of b-lactamase production among H. influenzae strains has been shown to vary among European countries [6] . Differences in empirical prescription guidelines and the availability of antimicrobial agents may contribute to differences in resistance in certain countries. This report summarizes data from a surveillance study of H. influenzae isolates collected from clinical laboratories in four European countries in 2000-2001. patients !18 years old, and 59 (7.0%) from patients of unknown age. Isolates were submitted to our central laboratory (Focus Technologies, Herndon, VA, USA) and subcultured on chocolate agar. The identity of each isolate was confirmed by using standard laboratory methods [7] , and each isolate was tested for the production of b-lactamase by use of the chromogenic substrate nitrocefin (BBL Dry Slide Nitrocefin, Becton Dickinson, Sparks, MD, USA).
M A T E R I A L S A N D M E T H O D S
Antimicrobial susceptibility to ampicillin, amoxicillin-clavulanate, cefaclor, cefuroxime, azithromycin, clarithromycin, roxithromycin, ciprofloxacin and levofloxacin was tested by broth microdilution according to the National Committee for Clinical Laboratory Standards (NCCLS) guidelines with the use of frozen microdilution panels (TREK Diagnostics, Westlake, OH, USA). Minimum inhibitory concentrations (MICs) for H. influenzae were interpreted using the NCCLS M100-S11 recommendations, where available [8] . The NCCLS-recommended quality control strains H. influenzae ATCC 49247 and H. influenzae ATCC 49766 were used throughout testing.
R E S U L T S
Of the 840 H. influenzae isolates collected, 18.8% (158/840) were b-lactamase positive and ampicillin resistant (France, 34.8%; Germany, 8.1%; Italy, 8.6%; Spain 23.8%) ( Table 1) . All of the isolates tested were susceptible to amoxicillin-clavulanate, ciprofloxacin and levofloxacin. Cefuroxime susceptibility was >96% in each country (Table 1) .
Overall, H. influenzae isolates collected from patients 4 years old had the highest prevalence of b-lactamase production (23.2%). b-Lactamase production was >5% lower among isolates collected from patients aged 5-17 years (17.8%) and !18 years (16.5%) than among patients 4 years old; this pattern was observed in all countries.
Macrolide activity was unaffected by b-lactamase production, as MIC distributions were similar for both b-lactamase-negative and b-lactamasepositive isolates (Figure 1) . In all countries, azithromycin (MIC 90 , 2 mg/L; !99% susceptible) was more potent than clarithromycin (MIC 90 , 16 mg/L; <83% susceptible) and roxithromycin (MIC 90 , 16 mg/L; no interpretive criteria) ( Table 1 ). Three azithromycin-non-susceptible H. influenzae isolates were collected (France, one isolate; Spain, two isolates); all were collected from respiratory specimens of male outpatients ranging in age from 4 to 37 years (data not shown). Azithromycin MICs for the three isolates were 8, 8 and >64 mg/L (confirmed by repeat testing), while clarithromycin and roxithromycin MICs were consistently higher (16, 32 and >128 mg/L for both agents; data not shown).
D I S C U S S I O N
The prevalence of b-lactamase production reported here (18.8%) is similar to that previously reported in other studies of H. influenzae in Europe [6, 9, 10] . The 2000 SENTRY study reported a blactamase prevalence of 12.6% [9] . The 1998 Alexander Project, which included France, Germany and Italy among the 14 countries studied, reported the prevalence of b-lactamase production to be 11.6% [10] . A 1997-98 European surveillance study performed by Sahm et al reported b-lactamase production among H. influenzae isolates collected from five countries to be 19.4% [10] . On a per country basis, Sahm et al reported b-lactamase frequencies similar to those observed here: France, 27.6%; Germany, 5.7%; Italy, 7.7%; and Spain, 32.0% [10] . In the USA, the frequency of b-lactamase production has been reported to be as high as 33% [11] , which is similar to the frequencies observed in France and Spain. While overall frequencies of b-lactamase production in the USA have reached a plateau [12, 13] , the frequency detected here was slightly higher than in previous years, suggesting that, in some European countries, b-lactamase production may be increasing.
Historically, azithromycin has been shown to be more active than erythromycin against Gramnegative organisms, due to the positive charge created by a methyl-substituted nitrogen in the 15-membered macrolide ring [14, 15] . Based on the MIC 90 in this study, azithromycin (2 mg/L in all countries) was more potent than both clarithromycin (16 mg/L in all countries) and roxithromycin (16 mg/L in all countries). Macrolide potency was unaffected by b-lactamase production. The MIC 90 s reported here for azithromycin were identical to those reported in the 1997-98 European surveillance by Sahm et al [6] ; however, the clarithromycin MIC 90 of 16 mg/L was one doubling dilution higher than this study, but identical to that reported in the 2000 SENTRY study [9] . The MIC 90 of roxithromycin was one dilution lower (16 mg/L) than reported in previous studies [2, 16] . The MIC 90 s of both azithromycin and clarithromycin were identical to those reported in the USA during the 1990s [13, 17, 18] , suggesting that the overall potencies of the macrolides against clinical isolates of H. influenzae have not changed in recent years.
Three azithromycin-non-susceptible H. influenzae isolates were collected, one of which demonstrated an azithromycin MIC of >64 mg/L and clarithromycin and roxithromycin MICs of >128 mg/L. These unusually high MICs were also reported in the 1992-97 Alexander Project [19] , as two isolates collected in 1997 were found to have azithromycin MICs !32 mg/L. Further work is necessary to determine the mechanism of resistance for these types of isolate.
Overall, >99% of the H. influenzae isolates tested were susceptible to amoxicillin-clavulanate, ciprofloxacin, levofloxacin and azithromycin, despite variations in b-lactamase production among countries.
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